N NT-proBNP HUY
NG NGN HN  BNH NHÂN HI CHNG VÀNH CP

Trn Vit An
1
,

2
,

3
1
ng i hc C
2
Trường Đại học Y Dược Huế;
3
Bệnh viện Trung ương Huế 
 k-

-
 t

 g-

(EF= 45-     -     
--
-pr

 Theo
-
-42%.
 



-


-





-

       -proBNP


-

-




 



I
II
III
IV
0
21
43
64
< 80
80-99
100-119
120-139
140-159
160-199

63
58
47
37
26
11
0
< 70
70-89
90-109
110-149
150-199

0

31



ST chên

 =  HCVC không có ST chênh lên







1  108
< 1
49  125
< 2
Trung bình
109  140
1  3
126  154
2  5
Cao
141 - 372
> 3
155 - 319

74,5 ± 19,4
73,6 ± 18,0
0,79

57,52 ± 10,79
65,69 ± 7,98
<0,001
NT-proBNP
1928,7
499,2
<0,001
GRACE
168,5 ± 30,4
118,6 ± 28,9
<0,001
B3.--IV

N

NT-proBNP (pg/ml)
n (%)
OR (95% KTC)
p
Trung bình
p
Killip I
103
3 (2,9)
6,67
(1,38-32,11)

50,0%
76,0%
 3.-

NT-proBNP



>2037 pg/ml
100%
76,7%
>3957 pg/ml
85,7%
90,0%
 
>1788 pg/ml
100%
73,3%
>3957 pg/ml
63,6%
90,5%
3.-
nhân HCVC




AUC
p
NT-proBNP (pg/ml)

92,5%


-
-

   -  [5] 
-proBNP là 545 pmol/L (157-1435 pmol/L) [8].
-

 
(OR= 4,6; 95% KTC= 3,85-   - 
-
II-IV) sau HCVC, 3964,3 pg/ml
[9]
--
[8].
-
   -proBNP
 là 809,7
--44%) là 2851,2 pg/ml (p
Estrada và cs n
-49%), trung bình (EF 30-
      -proBNP là 170,2 pg/ml, 333,7 pg/ml, 600,4
pg/ml và 1439,4 pg/ml (p <0,0001) [1]          -
 -54%, 40-49% và <40%) là
1123 pg/ml, 1394 pg/ml, 2170 pg/ml và 2564 pg/ml (p= 0,02) [2].
-

      -        r= -0,509; p

-
30-               -
-0,503; p <0,001).
-

0,917 (p <0,001).

+ NT-proBNP = (3 x GRACE) + (3.997 x log NT- 



1. Estrada N, Rubinstein F, Bahit MC, et al (2006), NT-probrain natriuretic peptide
predicts complexity and severity of the coronary lesions in patients with non-ST-
elevation acute coronary syndromes, Am Heart J, 151, pp.1100e1-1100e7.
2. Ezekowitz JA, Armstrong PW, Granger CB, et al (2010), Predicting chronic left
ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy,
Am Heart J, 160, pp.272-278.
3. Gale CP, Manda S, Weston CF, et al (2009), Evaluation of risk scores for risk
stratification of acute coronary syndromes in the Myocardial Infarction National Audit
Project (MINAP) database, Heart, 95, pp.221-227.
4. Jarai R, Iordanova N, Jarai R, et al (2007), Prediction of clinical outcome in patients
with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk
score extended by N-terminal pro-brain natriuretic peptide levels, Wien Klin
Wochenschr, 119, pp.626-632.
5. Khan SQ, Narayan H, Ng KH, et al (2009), N-terminal pro-B-type natriuretic peptide
complements the GRACE risk score in predicting early and late mortality following
acute coronary syndrome, Clin Sci, 117, pp.31-39.
6. Mayr A, Mayr J, Schocke M, et al (2011), Predictive value of NT-pro BNP after acute
myocardial infarction: Relation with acute and chronic infarct size and myocardial